Literature DB >> 207719

Use of isolated nuclei in the indirect fluorescent-antibody test for human cytomegalovirus infection: comparison with microneutralization, anticomplement, and conventional indirect fluorescent-antibody assays.

S Stagno, D W Reynolds, R J Smith.   

Abstract

Use of an antigen consisting of purified isolated nuclei from a mixture of human cytomegalovirus-infected and uninfected fibroblasts in a 2:1 ratio is a simple and reliable method for eliminating nonspecific fluorescence associated with the presence of Fc-immunoglobulin G receptors in the cytoplasm of infected cells. The specificity obtained with this antigen on 100 normal human sera was 99, 100, and 98% when compared with microneutralization, anticomplement immunofluorescence, and conventional indirect fluorescent-antibody assays, respectively. Also, 95% of the antibody titers obtained with the nuclear antigen had a perfect correlation with or were within a fourfold-dilution difference of the antibody levels obtained by anticomplement immunofluorescence and the conventional indirect fluorescent-antibody test.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 207719      PMCID： PMC275029          DOI： 10.1128/jcm.7.5.486-489.1978

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  10 in total

1.  Immunofluorescence and anti-complement immunofluorescence absorption tests for quantitation of Epstein-Barr virus-associated antigens.

Authors:  B M Reedman; J Hilgers; F Hilgers; G Klein
Journal:  Int J Cancer       Date:  1975-04-15       Impact factor: 7.396

2.  Solubilization of the Epstein-Barr virus-determined nuclear antigen and its characterization as a DNA-binding protein.

Authors:  J Luka; W Siegert; G Klein
Journal:  J Virol       Date:  1977-04       Impact factor: 5.103

3.  Indirect fluorescent-antibody test for human cytomegalovirus infection in the absence of interfering immunoglobulin G receptors.

Authors:  N S Swack; F J Michalski; A Baumgarten; G D Hsiung
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

4.  Microculture plaque assay for human and simian cytomegaloviruses.

Authors:  S Chiba; R L Striker; M Benyesh-Melnick
Journal:  Appl Microbiol       Date:  1972-04

5.  Comparative serial virologic and serologic studies of symptomatic and subclinical congenitally and natally acquired cytomegalovirus infections.

Authors:  S Stagno; D W Reynolds; A Tsiantos; D A Fuccillo; W Long; C A Alford
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

6.  Demonstration of immunoglobulin G receptors induced by human cytomegalovirus.

Authors:  T Furukawa; E Hornberger; S Sakuma; S A Plotkin
Journal:  J Clin Microbiol       Date:  1975-10       Impact factor: 5.948

7.  An IgG-Fc receptor induced in cytomegalovirus-infected human fibroblasts.

Authors:  R Keller; R Peitchel; J N Goldman; M Goldman
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

8.  Evidence for early nuclear antigens in cytomegalovirus-infected cells.

Authors:  L Geder
Journal:  J Gen Virol       Date:  1976-08       Impact factor: 3.891

9.  Immune complexes in congenital and natal cytomegalovirus infections of man.

Authors:  S Stagno; J E Volanakis; D W Reynolds; R Stroud; C A Alford
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

10.  Detection of early antigens in nuclei of cells infected with cytomegalovirus or herpes simplex virus type 1 and 2 by anti-complement immunofluorescence, and use of a blocking assay to demonstrate their specificity.

Authors:  G Giraldo; E Beth; U Hämmerling; G Tarro; F M Kourilsky
Journal:  Int J Cancer       Date:  1977-01       Impact factor: 7.396
  10 in total
  10 in total

Review 1.  Herpesviruses.

Authors:  M C Timbury; E Edmond
Journal:  J Clin Pathol       Date:  1979-09       Impact factor: 3.411

2.  Problems in detection of cytomegalovirus in urine samples by dot blot hybridization.

Authors:  S Augustin; T Popow-Kraupp; F X Heinz; C Kunz
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

3.  Micromodified cytomegalovirus antibody screening test.

Authors:  S M Henry; A M Ramirez; D G Woodfield
Journal:  J Clin Pathol       Date:  1985-01       Impact factor: 3.411

4.  Anticomplement immunofluorescence test that uses isolated fibroblast nuclei for detection of antibodies to human cytomegalovirus.

Authors:  L Mintz; R C Miner; A S Yeager
Journal:  J Clin Microbiol       Date:  1980-10       Impact factor: 5.948

5.  Application of a human osteogenic sarcoma cell culture for detection of human cytomegalovirus antibody by immunofluorescence tests.

Authors:  T Furukawa; R Herold; P Zolnick; S A Plotkin
Journal:  J Clin Microbiol       Date:  1981-01       Impact factor: 5.948

6.  Immunity to human cytomegalovirus measured and compared by complement fixation, indirect fluorescent-antibody, indirect hemagglutination, and enzyme-linked immunosorbent assays.

Authors:  J A Brandt; J D Kettering; J E Lewis
Journal:  J Clin Microbiol       Date:  1984-02       Impact factor: 5.948

Review 7.  Assessment of human cytomegalovirus antibody detection techniques.

Authors:  F Horodniceanu; S Michelson
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

8.  Immunofluorescence technique for detection of human cytomegalovirus (HCMV) antibodies against HCMV-induced late antigens with elimination of immunoglobulin G-receptor staining.

Authors:  M Tardy-Panit; S Michelson; F Horodniceanu
Journal:  J Clin Microbiol       Date:  1980-06       Impact factor: 5.948

9.  Enzyme-linked immunosorbent assay for measurement of antibody against cytomegalovirus and rubella virus in a single serum dilution.

Authors:  A M van Loon; J T van der Logt; J van der Veen
Journal:  J Clin Pathol       Date:  1981-06       Impact factor: 3.411

10.  Direct enzyme-linked immunosorbent assay that uses peroxidase-labeled antigen for determination of immunoglobulin M antibody to cytomegalovirus.

Authors:  A M van Loon; F W Heessen; J T van der Logt; J van der Veen
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.